Enfermedades neurodegenerativas: desarrollo de terapias

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Pazos MR, Mohammed N, Lafuente H, Santos M, Martínez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Martínez-Orgado J.

    Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT(1A) and CB2 receptors

    Neuropharmacology . 71: 282-291. Nº de citas: 132

    [doi:10.1016/j.neuropharm.2013.03.027]

  • Gómez del Rio MA, Sánchez-Reus MI, Iglesias I, Pozo MA, García-Arencibia M, Fernández-Ruiz J, García-García L, Delgado M, Benedí J.

    Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson's Disease.

    CNS NEUROL DISORD-DR . 12(5): 665-679.

  • Alvarado M, Decara J, Luque MJ, Hernandez-Folgado L, Gómez-Cañas M, Gómez-Ruiz M, Fernández-Ruiz J, Elguero J, Jagerovic N, Serrano A, Goya P, de Fonseca FR.

    Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21

    BIOORGANIC & MEDICINAL CHEMISTRY . 21(7): 1708-1716. Nº de citas: 16

    [doi:10.1016/j.bmc.2013.01.055]

  • Fernández-Fernández C, Decara J, Bermúdez-Silva FJ, Sánchez E, Morales P, Gómez-Cañas M, Gómez-Ruíz M, Callado LF, Goya P, Rodríguez de Fonseca F, Martín MI, Fernández-Ruíz J, Meana JJ, Jagerovic N.

    Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties

    ARCHIV DER PHARMAZIE . 346(3): 171-179. Nº de citas: 11

    [doi:10.1002/ardp.201200392]

  • Llorente-Folch I, Sahún I, Contreras L, Casarejos MJ, Grau JM, Saheki T, Mena MA, Satrústegui J, Dierssen M, Pardo B.

    AGC1-malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway

    JOURNAL OF NEUROCHEMISTRY . 124(3): 347-362. Nº de citas: 12

    [doi:10.1111/jnc.12096]

  • Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J.

    Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY . 75(2): 323-333. Nº de citas: 195

    [doi:10.1111/j.1365-2125.2012.04341.x]

  • Casarejos MJ, Perucho J, Gomez A, Muñoz MP, Fernandez-Estevez M, Sagredo O, Fernandez Ruiz J, Guzman M, de Yebenes JG, Mena MA.

    Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy

    JOURNAL OF ALZHEIMERS DISEASE . 35(3): 525-539. Nº de citas: 64

    [doi:10.3233/JAD-130050]

  • Granja AG, Carrillo-Salinas F, Pagani A, Gómez-Cañas M, Negri R, Navarrete C, Mecha M, Mestre L, Fiebich BL, Cantarero I, Calzado MA, Bellido ML, Fernandez-Ruiz J, Appendino G, Guaza C, Muñoz E.

    A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis

    JOURNAL OF NEUROIMMUNE PHARMACOLOGY . 7(4): 1002-1016. Nº de citas: 82

    [doi:10.1007/s11481-012-9399-3]

  • Pazos MR, Cinquina V, Gómez A, Layunta R, Santos M, Fernández-Ruiz J, Martínez-Orgado J.

    Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function

    Neuropharmacology . 63(5): 776-783. Nº de citas: 96

    [doi:10.1016/j.neuropharm.2012.05.034]

  • Ruiz C, Casarejos MJ, Rubio I, Gines S, Puigdellivol M, Alberch J, Mena MA, de Yebenes JG.

    The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins

    BRAIN RESEARCH . 1459: 100-112. Nº de citas: 8

    [doi:10.1016/j.brainres.2012.04.021]

  • de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández-Ruiz J.

    Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects

    Neuropharmacology . 62(7): 2299-2308. Nº de citas: 60

    [doi:10.1016/j.neuropharm.2012.01.030]

  • Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.

    Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington's Disease: Role of CB1 and CB2 Receptors

    ACS CHEMICAL NEUROSCIENCE . 3(5): 400-406. Nº de citas: 58

    [doi:10.1021/cn200114w]

  • Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J.

    Cannabinoids: novel medicines for the treatment of Huntington's disease.

    Recent patents on CNS drug discovery . 7(1): 41-48.

  • Cumella J, Hernández-Folgado L, Girón R, Sánchez E, Morales P, Hurst DP, Gómez-Cañas M, Gómez-Ruiz M, Pinto DC, Goya P, Reggio PH, Martin MI, Fernández-Ruiz J, Silva AM, Jagerovic N.

    Chromenopyrazoles: Non-psychoactive and Selective CB1 Cannabinoid Agonists with Peripheral Antinociceptive Properties

    Chemmedchem . 7(3, SI): 452-463. Nº de citas: 26

    [doi:10.1002/cmdc.201100568]

  • Perucho J, Casarejos MJ, Gomez A, Solano RM, de Yébenes JG, Mena MA.

    Trehalose protects from aggravation of amyloid pathology induced by isoflurane anesthesia in APP(swe) mutant mice.

    CURR ALZHEIMER RES . 9(3): 334-343.

  • Moreno-Martet M, Mestre L, Loría F, Guaza C, Fernández-Ruiz J, de Lago E.

    Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases

    NEUROSCIENCE LETTERS . 508(2): 67-72. Nº de citas: 10

    [doi:10.1016/j.neulet.2011.12.020]

  • Ruiz C, Casarejos MJ, Gomez A, Solano R, de Yebenes JG, Mena MA.

    Protection by glia-conditioned medium in a cell model of Huntington disease.

    PLoS currents . 4: .

    [doi:10.1371/4fbca54a2028b]

  • Solano RM, Casarejos MJ, Gómez A, Perucho J, de Yébenes JG, Mena MA.

    Parkin Null Cortical Neuronal/Glial Cultures are Resistant to Amyloid-beta(1-42) Toxicity: A Role for Autophagy?

    JOURNAL OF ALZHEIMERS DISEASE . 32(1): 57-76. Nº de citas: 11

    [doi:10.3233/JAD-2012-120406]